Drugs / Salmeterol / fluticasone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03745261 Background | Jun 2018 → Dec 2019 | chronic obstructive pulmonary disease | Henan University of Traditional Chinese Medicine | Unknown | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-08-31 | Novartis Pharmaceuticals | AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmeterol / fluticasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03745261 ↗ |
| Known as | Seretide | “Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations.” NCT03745261 ↗ |
| Route | Inhaled | “60 inhalations” NCT03745261 ↗ |